Background
inflammation, cirrhosis
INFLAMMATION, ALCOHOL-RELATED LIVER DISEASE, CIRRHOSIS
Alcohol is the leading cause of liver-related mortality worldwide. The gut–liver axis is considered a key driver in alcohol-related liver disease. Rifaximin-α improves gut-barrier function and reduces systemic inflammation in patients with cirrhosis. We aimed to compare the efficacy and safety of rifaximin-α with placebo in patients with alcohol-related liver disease.